Gastrin-releasing peptide receptor is a promising target for cancer diagnosis and therapy. However, the high pancreas uptake of reported GRPR-targeted radioligands limits their clinical applications. Our group previously reported one Ga-labeled GRPR antagonist, [Ga]Ga-TacsBOMB5 (Ga-DOTA-Pip-[D-Phe,NMe-Gly,LeuψThz]Bombesin(6-14)), and two agonists, [Ga]Ga-LW01110 (Ga-DOTA-Pip-[D-Phe,Tle,NMe-His,Thz]Bombesin(6-14)) and [Ga]Ga-LW01142 (Ga-DOTA-Pip-[D-Phe,His,Tle,NMe-His,Thz]Bombesin(6-14)) showing minimal pancreas uptake. Thus, in this study, we prepared their Lu-labeled analogs, evaluated their therapeutic potentials, and compared them with the clinically evaluated [Lu]Lu-AMBA. : GRPR binding affinities were determined by in vitro competition binding assay using PC-3 prostate cancer cells. Longitudinal SPECT/CT imaging and ex vivo biodistribution studies were conducted in PC-3 tumor-bearing mice. Dosimetry data were calculated from the biodistribution results. : The K(GRPR) values of Lu-TacsBOMB5, Lu-LW01110, Lu-LW01142, and Lu-AMBA were 12.6 ± 1.02, 3.07 ± 0.15, 2.37 ± 0.28, and 0.33 ± 0.16 nM, respectively. SPECT/CT images and biodistribution results demonstrated good tumor accumulation of [Lu]Lu-TacsBOMB5, [Lu]Lu-LW01110, and [Lu]Lu-LW01142 at early time points with rapid clearance over time. The pancreas uptake of all three [Thz]Bombesin(6-14)-derived ligands was significantly lower than that of [Lu]Lu-AMBA at all time points. The calculated absorbed doses of [Lu]Lu-TacsBOMB5, [Lu]Lu-LW01110, and [Lu]Lu-LW01142 in PC-3 tumor xenografts were 87.1, 312, and 312 mGy/MBq, respectively, higher than that of [Lu]Lu-AMBA (79.1 mGy/MBq), but lower than that of the previously reported [Lu]Lu-RM2 (429 mGy/MBq). : Our data suggest that [Lu]Lu-TacsBOMB5 and [Lu]Lu-LW01142 reduce radiation exposure to the pancreas. However, further optimizations are needed for both radioligands to prolong their tumor retention and enhance treatment efficacy.